Beijing founders can research early company builders, enterprise and frontier-technology specialists, consumer investors and growth strategies. The fastest useful shortlist starts with the company’s evidence and next milestone, then uses the local team and correct founder route to make the approach specific.
Compare 17 provider families, including 8 documented local or regional routes. Start with the decision framework, use the comparison to screen candidates and save the evidence in the worksheet before you approach anyone.
Choose a Beijing route that fits the business and first investment stage
| Your situation | Research first | Prepare or clarify |
|---|---|---|
| First institutional round or founder formation | Research ZhenFund, the relevant early venture team or MiraclePlus’s actual programme terms. | Separate product insight, cohort participation and a completed investment decision. |
| Enterprise AI or cloud software | Compare Eminence, appropriate Qiming/Vertex teams and relevant wider specialists. | Prepare the business buyer, deployment and commercial evidence. |
| Frontier science, hardware or advanced technology | Research Linear and the appropriate China technology strategies. | Explain the demonstrated result and next real-world development test. |
| Consumer technology or a scaling operating business | Compare Intonation’s China arm or the appropriate Ince/Legend strategy. | Do not transfer the US early-stage screen or growth criteria to every China vehicle. |
Choose a small first wave you can research properly. Record one reason for fit, one relevant proof point and the next unanswered question for each investor. Move a name out of the active queue when the stage, sector or geographic conditions do not fit.
Compare 17 local and wider investor routes
The connection column distinguishes a documented city or regional route from a wider mandate. It does not imply that every provider has an office here. Initial investment stages and follow-on support are different. This selective list is unranked; each provider family counts once.
| Investor or network | Connection | Entry-stage distinction | Company focus |
|---|---|---|---|
| Vertex Ventures China | Local / regional: China team with Beijing, Shanghai and Shenzhen offices | Early-stage investments; fund-specific | Technology; advanced manufacturing; biomedicine |
| Qiming Venture Partners | Local / regional: Beijing office; China strategies | Early and growth stages | Technology and healthcare innovation |
| Gobi China | Local / regional: China team based in Shanghai and Beijing | Early stage; vehicle-specific | Technology businesses |
| Linear Capital | Wider route: China-linked technology investor with international examples | Angel through Series A | AI software and hardware; science and manufacturing |
| Jingwei Venture Capital | Wider route: China-focused strategy in its Chinese-language overview | Early and early-growth stages | Software; technology; advanced manufacturing; consumer |
| Ince Capital | Local / regional: Shanghai, Beijing and Hong Kong offices | Early through expansion | AI; technology; consumer; biotechnology |
| Lighthouse Yuanzhan Capital | Wider route: China-based manager with China and US startup activity | Early stage | Technology products and commercialization |
| Lingfeng Capital | Wider route: Greater China and ASEAN focus with other selective exposure | Early through growth; vehicle-specific | Digital finance; industrial technology; AI and data |
| Next Capital | Wider route: Published founder-investment history includes China's technology market | First investment and early stage | Technology startups; company-specific |
| Eminence Ventures | Wider route: Published China enterprise-cloud focus | Early stage | Enterprise software and cloud computing |
| XVC | Local / regional: Beijing contact and China-linked portfolio examples | Confirm current entry stage | Platforms; data-driven applications; company-specific technology |
| EdgeVentures | Wider route: China-connected manager; verify the current fund's geographic remit | Angel through Series A emphasis; later participation varies | Internet; technology; consumer services |
| Intonation Ventures | Local / regional: Describes a Beijing investment arm and China investment activity | China stage varies; US early-stage strategy is separate | Consumer technology; gaming; wellness; marketplaces |
| MiraclePlus | Wider route: Early-stage accelerator for startups in China | Early-stage cohort; terms and timing may change | Startup and technology companies |
| Legend Capital | Local / regional: Beijing headquarters | Early venture and growth strategies differ | Technology; enterprise; manufacturing; health and other themes |
| ZhenFund | Local / regional: Beijing-rooted founder and technology ecosystem | Early stage | Technology across sectors |
| Sinovation Ventures | Wider route: China technology platform; USD and RMB vehicles | Strategy-specific venture; confirm entry round | Technology and innovation |
A Beijing founder brief should state what is proven and what is next
The same introduction email should not be sent unchanged to an enterprise-cloud specialist, a consumer-technology team and a founder accelerator. State the product, intended user, current evidence and what the next round would establish. A scientific demonstration, a pilot, signed revenue and repeatable growth are different states.
The national China venture-capital guide remains central. This Beijing guide adds a comparison between local founder routes, technical specialists and company-growth strategies. It does not imply that every wide-mandate firm has a Beijing office.
Find the company pitch route before sending the deck
ZhenFund’s current About page publishes a BP route separate from media contact. Qiming similarly separates founder submissions from general and media enquiries. A public company pitch channel is not the same as a fund-investor, recruiting or events address.
Use an authorized short description and current evidence before sharing sensitive details. A real introduction can add relevant relationship context, but it should not bypass explicit instructions or imply that someone endorses a company without permission. Keep a clear owner and next action for every open conversation.
Do not mix China, US, accelerator and growth criteria
Intonation describes a Beijing/China arm and a separate US strategy. Legend’s early venture and growth private-equity lanes are different. MiraclePlus combines investment with a founder programme whose current terms and timing matter. These are concrete decision filters, not interchangeable labels.
For each candidate, identify the current team and vehicle, expected entry evidence and public route. USD/RMB or company-structure questions need direct confirmation and appropriate professional advice, not assumptions from an unrelated portfolio round. Finta helps keep the research and relationship work connected; Aurora can help organize the brief for your review.
17 investors and networks to research
1. Vertex Ventures China
China venture fund team. Vertex China’s Beijing presence is useful for finding the appropriate technology investment team. A Beijing founder should state the product evidence and relevant current round. The local office is access context, not approval for every company or legal structure.
Approach: Official investment information. Official Vertex Ventures China information.
2. Qiming Venture Partners
Venture investment manager. Qiming’s Beijing office and public BP route make the initial approach clear. A Beijing company should identify the actual technology or healthcare strategy and current stage. The relevant vehicle and company structure need confirmation rather than assumptions from a previous portfolio round.
Approach: Use BP submission on the official Contact page. Official Qiming Venture Partners information. Additional criteria or geographic context.
3. Gobi China
Early-stage venture manager. Gobi China lists Beijing presence alongside Shanghai. A Beijing founder should identify the relevant China team and initial company-stage criteria. A wider Gobi portfolio in another region is not evidence of the same mandate.
Approach: Official investment information. Official Gobi China information.
4. Linear Capital
Frontier-technology venture investor. Linear’s angel-to-Series-A focus can be researched by a Beijing frontier-technology team. Explain the application, scientific or engineering result and first practical buyer. Broad national reach does not replace company-stage and sector fit.
Approach: Official investment information. Official Linear Capital information.
5. Jingwei Venture Capital
China venture investment manager. Jingwei’s China-focused early and early-growth strategy is a wider route for a Beijing technology company. Describe the operating evidence and next milestone. Do not confuse the legacy Matrix China name with a second independent manager.
Approach: Official investment information. Official Jingwei Venture Capital information.
6. Ince Capital
Early-to-expansion venture firm. Ince’s Beijing office provides a local relationship starting point. Explain whether the proposed round funds validation or expansion and which current strategy fits. Office presence and broad sector coverage are different pieces of evidence.
Approach: Official investment information. Official Ince Capital information.
7. Lighthouse Yuanzhan Capital
Early-stage venture investor. Lighthouse adds a wider early commercialization route for a Beijing company. Explain the product and next operating milestone. National or cross-border activity does not imply a local office or unconditional funding availability.
Approach: Official investment information. Official Lighthouse Yuanzhan Capital information.
8. Lingfeng Capital
Regional technology venture manager. Lingfeng adds a wider Greater China/ASEAN lane for a Beijing technology company. A founder should present current customer or industrial evidence and identify the relevant strategy. Do not treat all vehicles and stages as equivalent.
Approach: Official investment information. Official Lingfeng Capital information.
9. Next Capital
Early-stage venture investor. Next can be researched for a Beijing company near its first institutional financing. State the product evidence and intended initial market. Identify the actual current route instead of converting a manager’s history into a guaranteed stage rule.
Approach: Official investment information. Official Next Capital information.
10. Eminence Ventures
Enterprise-cloud venture firm. Eminence’s early enterprise-cloud focus is a wider research lane for Beijing B2B founders. Bring the buyer, deployment context and product evidence. Confirm the current initial-stage criteria rather than infer them from a later portfolio round.
Approach: Official investment information. Official Eminence Ventures information.
11. XVC
Technology venture investor. XVC publishes a Beijing contact and a technology investment proposition. Explain the platform or data-driven product and current company evidence, then confirm the relevant initial round. Do not replace an unresolved stage criterion with a guessed seed label.
Approach: Official investment information. Official XVC information.
12. EdgeVentures
Venture investment firm. Edge offers another wider early-stage comparison for a Beijing technology business. Identify the relevant company and vehicle criteria. Do not count a later follow-on as proof that the manager takes every new investment at that stage.
Approach: Official investment information. Official EdgeVentures information.
13. Intonation Ventures
Consumer-technology venture platform. Intonation describes a Beijing investment arm and China consumer-technology activity. A founder should connect the actual consumer, gaming, wellness or marketplace business to that strategy. Its separate US early-stage remit is not automatically the China-stage rule.
Approach: Official investment information. Official Intonation Ventures information.
14. MiraclePlus
Investment-backed accelerator. MiraclePlus is an investment-backed founder programme rather than a conventional stand-alone fund pitch. A Beijing team should review the current cohort and financing terms. Founder resources, programme participation and an executed investment are separate steps.
Approach: Official accelerator information. Official MiraclePlus information.
15. Legend Capital
Venture and growth private-equity manager. Legend’s Beijing headquarters is a local starting point, but the relevant venture or growth strategy still determines fit. Explain the business and current evidence, then confirm the actual investment team and vehicle. Avoid unofficial intermediaries claiming to represent the firm.
Approach: Use official team/contact information; do not assume an LP contact is a company pitch route. Official Legend Capital information.
16. ZhenFund
Early-stage venture firm. ZhenFund’s current About page states an early-stage founder thesis and a public BP address. A Beijing founder should explain the team’s insight and what the product has established. The investment route is distinct from media, events and recruiting enquiries.
Approach: Use the published BP route, not media contact. Official ZhenFund information.
17. Sinovation Ventures
Technology venture firm. Sinovation is a wider China technology route for a Beijing company. A founder should identify the current team, vehicle and entry stage, then explain the product and business evidence. Its investment, portfolio support and fund-investor enquiries are separate activities.
Approach: Use the current official company/team contact. Official Sinovation Ventures information. Additional criteria or geographic context.
A Beijing enterprise-AI company keeps the first wave focused
Fictional worked example. A fictional Beijing team has an enterprise AI product, two trials and no repeatable revenue. The assumed funding task is to validate a paid deployment and security-review process. The example does not describe a Finta customer or any investor outcome.
| Candidate | Next action | Why it changes the decision |
|---|---|---|
| Eminence / relevant Qiming or Vertex team | Prepare the enterprise workflow, product evidence and next customer milestone. | The company can explain actual buyer value without claiming mature distribution. |
| ZhenFund | Research early-company fit and use the published BP route. | An early product and founder insight can be described honestly. |
| MiraclePlus | Review current participation and financing terms. | A programme-linked investment is a different commitment from a conventional fund meeting. |
| Intonation / growth strategies | Include only if the actual consumer or company-maturity criteria fit. | Enterprise AI is not automatically a consumer strategy or a growth-stage business. |
The aim is a more coherent queue, not the largest possible one. Connect the proposed round with an achievable milestone using the round-size planning worksheet.
Build your Beijing investor-fit worksheet
Use one card for each provider and strategy. It works in a document, spreadsheet or your Finta research notes. Keep facts, expectations and questions in separate fields.
INVESTOR FIT CARD: BEIJING
Company, current evidence and next funding milestone: [authorised facts]
Beijing/local team versus wider investment connection
Business buyer or consumer user and current product evidence
Initial entry round, follow-on support and company-growth lane: distinguish
China versus US strategy and actual currency vehicle: source/question
Founder BP route and information authorized for the initial brief
Investor and specific vehicle: [current name; avoid rebrand duplicates]
Official stage, sector and geographic criteria: [URL; date]
Fit evidence: [what matches; not just a portfolio resemblance]
Mismatch or open question: [the unresolved issue]
Approach route: [founder form / network selection / general enquiry]
Relationship context: [known person; permission to ask; or public route]
Lead/co-investment status: [unknown / conditional / confirmed]
Owner, next action and follow-up date: [person; action; date]Bring the shortlist into Finta to keep investor research, relationship context and follow-up connected. Aurora can help organise the context and prepare a next move for your review. You stay in control of the approach and information shared.
Review your shortlist with Aurora, Claude or Codex
Paste the prompt with the public sources and company information you are authorised to use. Check its output against the sources before acting.
Help me research investor fit for a Beijing startup.
Company, location, current evidence and funding milestone: [authorised facts]
Candidates and official sources: [names, URLs and research dates]
Separate local offices, regional operating requirements and wider investment eligibility.
Check the specific vehicle, initial stage, sector, company conditions and public approach route.
Keep university programmes, angel networks, direct equity, grants and commercial partnerships distinct.
Count each manager or rebrand once. Do not assume a portfolio investment proves current eligibility.
Return a table: source, fit evidence, mismatch, unknown, next question and owner.
Flag missing or contradictory evidence instead of filling gaps.
Suggest a short first research wave and explain exclusions.
Do not contact anyone, submit forms or share confidential information.Keep the wider fundraising process connected with the pre-seed guide, Seed Fundraising Comprehensive Guide and investor-prospecting workflow. For national coverage, see the China investor guide.
Methodology and research date
By Finta Editorial Team. Official investor, public-institution and company materials reviewed November 13, 2026, with source-dated prior research used for discovery. 17 provider families are included: 8 documented local or regional routes and 9 wider mandates. Angel networks are identified as networks, not pooled funds. Company-building and strategic investment routes are labelled separately.
Startup Genome’s 2026 Emerging Ecosystems ranking informed city selection; it is not an investor ranking or endorsement. Current official materials support the profiles. A published thesis is not a promise of available capital, current intake or an investment outcome. Confirm open questions directly.
Not counted or kept separate:
- Intonation’s US early-stage strategy is not transferred to the China arm without evidence.
- MiraclePlus participation, educational resources and an executed investment are distinct.
- No investor names are counted again for additional offices, fund currencies or rebrands.
General information, not personalised financial, legal or tax advice. Programme and company criteria are research filters, not an eligibility ruling. The cover is an editorial ecosystem illustration, not a map of investor offices or actual financing flows.